Madrigal Pharmaceuticals MDGL
Healthcare · Biotechnology · Synthos Deep Dive · 2026-07-06
The Overview
Madrigal sells Rezdiffra (resmetirom), the first medicine ever approved in the U.S. for MASH — a serious fatty-liver disease that can scar the liver and previously had no approved drug at all. Being first into a big untreated disease is why sales exploded from nothing to almost a billion dollars in about two years.
The catch comes in three parts. First, this is a one-product company — if anything slows Rezdiffra, there is no second act on the market. Second, the competition is coming: the wildly popular weight-loss drug class (GLP-1s) is moving into the same disease, and those drugs treat the obesity that causes MASH in the first place. Third, the price already assumes success: you're paying about eleven times sales for a company that still loses money, and last quarter sales actually dipped slightly from the quarter before — the first wobble in the launch.
Here's what our three scores mean in everyday terms:
- Downside Risk 8/10 (high). Cash in the bank is solid (~$984M), but one product, ongoing losses, a rich price tag, and new competitors is a fragile combination — if the story cracks, the fall is steep.
- Growth Quality 6/10 (decent, unproven). The growth is spectacular and the margins on each pill are excellent, but the company hasn't yet shown it can turn that into actual profit — analysts think that happens next year.
- Exponential Potential 7/10 (high). If the launch keeps climbing the way Wall Street models it, sales could grow five-fold by 2030 and the stock has real room. But growth is slowing down each year, not speeding up.
The one big worry: a slowing launch. Sales dipped quarter-over-quarter for the first time. If that happens again in August, the "five-fold by 2030" math the price depends on starts to look like a story, and an expensive one.
Putting a number on it: our fair-value estimate is $610 against a current price of $527.82 — real upside if our numbers are right.
Our summary metrics
Single-commercial-asset biotech burning ~$190M/yr of FCF at 10.9× EV/sales with GLP-1 competition inbound and a −$2.1B retained deficit; $984M of cash & investments and a 3.5× current ratio are the only brakes. The printed beta of −1.06 is a data artifact, not a hedge.
Revenue +432% in FY25 on a 93% gross margin, but the company is still −27% net margin, ROE −50%, one product, and FY27E is the first profitable year — on just 8 analysts' numbers.
Street sees revenue ~5× to $5.1B and EPS $64.89 by 2030 from a $12.2B cap — genuine room to run — but growth is decelerating (+55% → +26% by FY30E), not accelerating, and it is a one-molecule bet.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, We don’t publish a reverse-DCF cross-check for pre-profit companies — negative or missing earnings break that math — so take this number on our modeling alone.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Street sees revenue ~5× to $5.1B and EPS $64.89 by 2030 from a $12.2B cap — genuine room to run — but growth is decelerating (+55% → +26% by FY30E), not accelerating, and it is a one-molecule bet.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Clinical pipeline
4 of 4 active/recent trials shown, ranked by phase and status. Source: ClinicalTrials.gov, live at render time. Timeline notes are general regulatory-process norms, not a Synthos prediction for this specific trial.
Resmetirom
Condition: NASH, Cirrhosis, Liver
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a…
Phase 3 — if positive, this typically supports an FDA submission within 6–12 months, with standard review adding roughly another 10–12 months before a possible approval.
View on ClinicalTrials.gov (NCT05500222)Resmetirom
Condition: Non-Alcoholic Fatty Liver Disease
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Phase 3 — if positive, this typically supports an FDA submission within 6–12 months, with standard review adding roughly another 10–12 months before a possible approval.
View on ClinicalTrials.gov (NCT04951219)MGL-3196, Liver Biopsy
Condition: NASH - Nonalcoholic Steatohepatitis
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis…
Phase 3 — if positive, this typically supports an FDA submission within 6–12 months, with standard review adding roughly another 10–12 months before a possible approval.
View on ClinicalTrials.gov (NCT03900429)Resmetirom
Condition: MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver…
Phase 2 — successful results would typically move this into pivotal Phase 3 testing, several years from a possible approval.
View on ClinicalTrials.gov (NCT07335601)Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $668.83 (high $964 / low $542; 20 Buy · 2 Hold · 1 Sell) — context, not our anchor |
| Valuation | No trailing P/E (loss-making: TTM EPS −$10.66) · EV/S 10.9× · P/S 10.8× · P/B 28.3× · FY27E P/E ~53× → FY28E ~19× → FY30E ~8× |
| Technicals | Stretched — $529 above the 50-DMA ($509) and 200-DMA ($498), RSI 73 (overbought), −12% off the 52-wk high ($603), +76% 12-mo (SPY +21%) but −3% 3-mo / −9% 6-mo |
| Conviction | None — 0 KB claims, 0 voices. Fundamentals-driven note on a screen-surfaced name; treat accordingly |
| Position sizing | None yet — Watch. If triggered (~$470 or a clean Q2 print), satellite-only, ~0.5–1.5% |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for MDGL — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $533.76, 1% above the 50-day average ($527), 4% above the 200-day average ($515) — an uptrend. 11% below the 52-week high of $603, 29% above the 52-week low of $412.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $533.76 is currently inside the band (band $490–$549).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 53.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 2.33, positive momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = MDGL · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a commercial-stage biopharmaceutical company focused on liver and cardiometabolic disease. Its franchise is Rezdiffra (resmetirom) — a liver-targeted, selective thyroid hormone receptor-β agonist and the first FDA-approved therapy for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) with moderate-to-advanced fibrosis. Headquartered in West Conshohocken, PA; CEO William J. Sibold; 528 employees — a deliberately lean commercial organization for a ~$1B-revenue drug. IPO lineage dates to 2007 (via reverse merger). Data caveat: the FMP profile text still describes Madrigal as "clinical development phase" — that is stale; the income statement shows a commercial company with $958M of FY25 product revenue.
Revenue mix — there is no mix. The FY25 segment disclosure shows a single reportable segment: $958.4M. Geographic segmentation is empty in the data file (the launch is U.S.-led; ex-U.S. expansion is a forward story we cannot quantify from this file). This is the cleanest possible illustration of the core risk: one drug, one indication, effectively one market. The pipeline behind it (per the profile, a backup compound and the legacy Roche collaboration) generates no disclosed revenue; the R&D line — $388.5M in FY25, up 64% YoY, and $108.7M in Q1 2026 alone (+146% YoY) — says management is spending heavily to build what comes next (combinations, earlier-stage fibrosis, lifecycle work), but nothing in this data file lets us underwrite it.
2. The expert thesis — why the panel is bullish (traceable)
No expert-panel coverage — this note is fundamentals-driven. A search of the Synthos knowledge base returns zero traceable claims on MDGL across all voices. There is no Visser, no ecosystem endorsement, no management transcript in the KB — nothing to cite, so nothing is cited. That is the honest house standard for a screen-surfaced name: this company entered coverage via the quant momentum screen, not via conviction voices.
What that means practically:
- Conviction rating: None. The verdict below rests entirely on the FMP fundamentals, analyst estimates, and technicals in the data file — a thinner evidentiary base than a panel-backed name, and the sizing guidance in §12 reflects that.
- No independent bear thesis either. The bear case in §3 is constructed from the fundamentals (launch-curve math, competitive logic, burn rate), not from a countervailing expert.
- Street coverage exists and is heavily bullish (20 Buy / 2 Hold / 1 Sell, consensus target $668.83) — we show it as context, but sell-side consensus is not the Synthos conviction pool and gets zero conviction weight.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 8 · Very High | One commercial molecule, TTM FCF −$252M (firm) / burn ~$190M FY25, EV/S 10.9×, P/B 28.3×, retained deficit −$2.09B, GLP-1 competition entering the indication, and a first sequential revenue dip already in the price action. Against that: $984M cash & short-term investments, net debt only $156M, current ratio 3.5× — funded, not fragile. The printed beta of −1.06 is an artifact of idiosyncratic biotech moves, not a market hedge. |
| Growth Quality | 6 · High | Revenue +432% FY25 ($180M → $958M) on a 93.1% TTM gross margin — elite unit economics. But net margin is −27.3%, ROE −50%, SG&A eats 81% of revenue (TTM), and the first profitable year (FY27E, EPS +$9.93) is still a forecast — from only 8 analysts. Quality is plausible, not yet demonstrated. |
| Exponential Potential | 7 · High | Street models revenue $958M → $5.08B by 2030 (~5.3×) and EPS reaching $64.89, from a $12.2B cap — genuine multibagger room if it lands. But the growth rate decelerates every year (+55% FY26E → +50% → +36% → +33% → +26%): this is a fast S-curve, not an accelerating exponential, and it is one molecule wide. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Launch reaccelerates (Q1 dip proves to be copay-reset seasonality), ex-U.S. adds a leg, GLP-1s expand the diagnosed-MASH funnel rather than displace Rezdiffra; FY29E EPS ~$45 earns a ~25× growth-pharma multiple, discounted ~2.5 yrs at 9%. | ~$900 (+70%) |
| Base (our anchor) | Consensus roughly lands — FY28E EPS $27.52 at a ~25× forward multiple ≈ $688 end-2027 value, discounted ~18 months at 9% ≈ ~$605–610; sits essentially on the Street median ($613.50). | ~$610 (+15%) |
| Bear | The launch curve flattens: GLP-1 competition + payer friction cap revenue near the FY26 run-rate (~$1.5B), profitability slips past FY27, and the market re-rates to ~4× EV/S on a stalled story ≈ ~$260/share — just under the 52-week low ($288). | ~$260 (−51%) |
Synthos fair value = the base case, ~$610 (+15%), with the full $260–$900 span as the honest range. Our base sits below the Street's $668.83 consensus and on its $613.50 median — we anchored the same FY28 earnings power but applied a plainer multiple. The asymmetry is the tell: +15% to base, −51% to bear — a payoff profile that argues for waiting for either a better price or a cleaner print. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MDGL is a high-potential S-curve, not a true accelerating exponential:
- Forward growth: consensus revenue CAGR 2025→2030 of ~40%/yr ($958M → $1.49B → $2.23B → $3.03B → $4.03B → $5.08B); EPS swings from −$7.21 (FY26E) to +$9.93 (FY27E, first profit) → $27.52 → $45.14 → $64.89 (FY30E) — enormous operating leverage on a 93% gross margin once SG&A/R&D stop outgrowing sales.
- Acceleration (the 2nd derivative) is negative: +432% (FY25 actual) → +55% (FY26E) → +50% → +36% → +33% → +26% (FY30E). Every year is slower than the last. That is normal launch math, but it is the opposite of the accelerating profile that earns a 9–10 here.
- Room to run: $12.2B market cap against $5.1B of modeled 2030 revenue and $64.89 of modeled 2030 EPS — at even 15× that EPS the stock would roughly double. The room is real; the path is a single molecule's share of a newly contested indication.
- Estimate quality caveat: the out-year numbers rest on 5 revenue / 4 EPS analysts (2029–2030) vs 11 for 2026–2028 — the far bars are sketches, not forecasts. (The FMP out-year SG&A estimate rows are internally inconsistent — SG&A above revenue — and we disregard them.)
Exponential Potential: High (7/10). Genuine multibagger geometry if the launch holds, docked for deceleration, single-asset concentration, and thin out-year coverage.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $958.4M, +432% (FY24 $180.1M; FY23 zero — the launch began mid-2024). TTM revenue ~$1.13B.
- Quarterly trajectory (the wobble): Q1'25 $137.3M → Q2 $212.8M → Q3 $287.3M → Q4 $321.1M → Q1'26 $311.3M. That is +127% YoY but −3.0% sequentially — the first QoQ decline of the launch. U.S. pharma Q1s often dip on copay resets and channel destocking (context, not from the file), but for a stock priced on the launch curve, this is the number to watch on 2026-08-04. Q1'26 revenue did beat the Street's $301.1M estimate.
- Margins: gross 93.1% TTM — pharma-grade unit economics. But operating margin is −27.7% TTM: FY25 operating loss −$300.1M (R&D $388.5M + SG&A $813.8M against $902M gross profit). The loss is narrowing per quarter in relative terms (Q4'25 −$59.6M op loss on $321M revenue; Q1'26 −$92.7M, wider again on the R&D step-up to $108.7M).
- Earnings: FY25 net −$288.3M, EPS −$12.85 (improved from FY24's −$21.90). Q1'26 net −$94.4M, EPS −$3.25 — a beat vs the −$3.61 estimate. The company has beaten the EPS estimate in 3 of the last 4 prints (the miss: Q3'25, −$5.08 vs −$2.04 est, on the R&D/SG&A ramp).
- Cash flow: FY25 operating CF −$189.6M, capex trivial (−$0.5M), FCF −$190.0M — less than half FY24's −$457M burn. Stock comp $98.1M FY25 (~7.5% of TTM revenue). Income quality 0.87.
- Balance sheet: cash + short-term investments $983.6M vs total debt $354.4M (net debt $155.7M) — FY25 added $217.9M of new debt and $38.1M of equity issuance. Current ratio 3.5×, working capital $844M. At the FY25 burn rate (~$190M), the balance sheet funds 4–5 years — the launch, not financing, is the binding risk. Retained deficit −$2.09B; equity $602.7M against a $12.2B cap explains the 28.3× P/B.
- Share-count caveat: the Q1'26 income statement reports 29.03M weighted-average shares vs 22.43M in Q4'25, yet the quote's market cap implies ~23.1M shares at $529.48 — an internal inconsistency in the data file we flag rather than resolve. Per-share figures for Q1'26 should be read with that caveat.
6. Valuation — priced in or room?
There is no trailing earnings multiple to lean on — the company loses money (TTM EPS −$10.66). What the data supports: EV/sales 10.9×, P/S 10.8×, P/B 28.3× — a premium even by commercial-biotech standards, and FMP's letter rating is a blunt C (overall 2/5; ROE, ROA, D/E, P/E, P/B all score 1/5 — only the DCF score, 5/5, likes it, which is exactly the shape of a story stock: terrible on trailing, attractive on modeled cash flows). The forward compression is the entire bull case: at $529.48, ~53× FY27E EPS ($9.93) → ~19× FY28E ($27.52) → ~12× FY29E ($45.14) → ~8× FY30E ($64.89) — the forward PEG prints 0.17. If the estimates land, today's price is cheap; if the curve flattens, there is no valuation floor above ~4× sales. Street targets (context): consensus $668.83 (+26%), high $964, low $542, median $613.50 — even the low target sits above today's price, which tells you how uniformly bullish (and therefore how crowded) the sell-side stance is. Our $610 base deliberately sits on the median, not the mean. Not a value buy; a launch-curve underwrite where the multiple is hostage to two or three quarterly prints.
7. Technicals (from the tech block)
- Trend: intact but tired. $529.48 sits above the 50-DMA ($508.69) and 200-DMA ($497.60), 50 above 200 — an uptrend on paper. MACD +7.18 (positive).
- Location: −12.2% off the 52-week high ($602.83) — also the max drawdown from peak — and +84.2% off the 52-week low ($287.52).
- Momentum (the warning): RSI(14) 72.95 — overbought. This is a stretched short-term entry by the house playbook.
- Relative strength (the tell): +76.4% over 12 months vs SPY +21.1% / QQQ +31.2% — a big winner. But the near lens has flipped: −3.2% over 3 months vs SPY +14.6%, and −9.1% over 6 months vs SPY +10.2%. The stock has been underperforming the market for six months while grinding sideways-to-up — momentum leadership has already rolled off.
- Read: technicals support patience, which is what the Watch verdict asks for anyway: overbought RSI into an earnings catalyst, with fading relative strength. The 200-DMA (~$498) and the round $470–480 zone below it are the natural accumulation areas if the fundamental trigger fires.
8. Moat & competitive position
Madrigal's moat is first-mover incumbency in a newly created market: the first approved MASH therapy, a 93% gross margin, the reference brand physicians learn first, and a two-year head start building the diagnostic and prescribing infrastructure for a disease that had none. In specialty pharma, that infrastructure — payer contracts, hepatologist relationships, patient identification — is a real, if soft, barrier. But the moat is one molecule wide and the siege is coming: the GLP-1 class (context: now approved in MASH) attacks the cause (obesity) rather than the liver downstream, and a deep industry pipeline is targeting the same fibrosis endpoints. The bull counter — GLP-1 noise expands MASH diagnosis rates and Rezdiffra wins the add-on/intolerant population — is plausible and unproven. ROE −50% and a −27% net margin say the moat has not yet translated into economics; the 93% gross margin says it can.
Peer set (FMP-supplied, market cap): a heterogeneous mid-cap healthcare list rather than clean comps — Moderna $32B, Jazz $15B, Exelixis $14B, Baxter $12B, BioMarin $11B, Bio-Techne $11B, Abivax $9.4B, Rhythm $7.7B, Caris $5.0B, Atrium $0.2B. The most relevant competitive comparators — the GLP-1 majors and the MASH pipeline names — are not in this supplied set: a data caveat. Within the list shown, MDGL carries by far the fastest growth and one of the richest sales multiples.
9. Management, capital allocation & guidance
- Capital allocation: classic launch-mode — every dollar into the ramp. FY25: R&D $388.5M (+64%), SG&A $813.8M (+87%), zero buybacks, zero dividend, funded by $217.9M of new debt plus $38.1M of equity. Raising debt at ~$1B of cash reads as runway insurance ahead of a competitive window — defensible, and cheaper than equity at these prices. Capex is negligible (asset-light: $6.4M of PP&E).
- Leadership: CEO William J. Sibold — a commercial-stage operator profile consistent with the company's pivot from R&D story to launch execution. The data file contains no compensation or tenure detail; we don't editorialize beyond it.
- Insider activity: the most recent Form 4s (filed 2026-06-18) are routine annual director grants — Taub, Levy, Fouse, and Daly each received 454 RSUs and 766 options struck at $499.86. No open-market buys or sells appear in the file. Neutral signal; the $499.86 strike is at least a marker of where the board's incentives are set.
- Management guidance: none is captured in our data pull (no earnings-call transcript in the KB, no guidance fields in the file) — we flag the absence rather than paraphrase from memory. The earnings calendar shows the Street expects Q2 2026 revenue of ~$349.8M and EPS of −$2.75.
10. Catalysts & what to watch
- Next earnings: 2026-08-04 (Q2 2026; Street EPS −$2.75, revenue ~$349.8M). This is the whole ballgame: $349.8M vs Q1's $311.3M would be +12% sequential and would retire the Q1-wobble concern; a second flat-to-down quarter validates the bear case.
- Sequential prescription/revenue trajectory — the single most informative datapoint each quarter for a launch-curve valuation.
- Competitive flow into MASH: GLP-1 uptake in the indication and next-wave pipeline readouts (context to monitor; not in the data file).
- Ex-U.S. expansion: geographic segment data is empty today — any disclosed international revenue would be a new leg for the model.
- Path-to-profitability markers: FY27E is consensus's first profitable year (EPS +$9.93); watch whether SG&A growth finally drops below revenue growth (SG&A was 81% of TTM revenue).
- Financing: none needed near-term ($984M vs ~$190M burn), so any capital raise would itself be a signal.
Thesis tripwires (what would change the call): a second consecutive sequential revenue decline; SG&A still outgrowing revenue by FY26 year-end; a competitive approval/readout that visibly bends the script trajectory; or price reaching ~$470 with the launch intact (upgrade trigger).
11. Key risks
- Single-asset concentration (the structural risk): one drug, one indication, one reportable segment. Anything — safety signal, label issue, competitive displacement — that hits Rezdiffra hits 100% of revenue.
- Competitive erosion: the GLP-1 class entering MASH attacks the disease upstream; a deep pipeline is behind it. The bull's "market expansion" counter-thesis is unproven.
- Launch-curve risk, already flickering: Q1 2026's −3% QoQ was the first sequential decline. Launch valuations die on flat quarters, not bad ones.
- Valuation / de-rating: 10.9× EV/S and 28× book with no earnings floor; our bear case (−51%) is a plain multiple-on-stalled-sales exercise, not a stress fantasy.
- Still unprofitable: −$288M FY25 net loss, −$190M FCF; profitability is a FY27 forecast on 8 analysts' numbers.
- Estimate fragility: out-year consensus (2029–30) rests on 4–5 analysts, and parts of the FMP estimate file are internally inconsistent (out-year SG&A rows exceed revenue) — the far-out numbers deserve wide error bars.
- Data-quality caveats: printed beta (−1.06) is unusable; the Q1'26 share count conflicts with the quoted market cap; the profile description is stale. All flagged in §5 and Provenance.
- No expert-panel underwriting: zero KB voices means no independent conviction check on our fundamental read — a reason for conservatism in itself.
12. Verdict, position sizing & monitoring
Watch. Madrigal is a genuinely rare asset — the first approved therapy in a large, previously untreated disease, scaling from zero to a ~$1.3B annualized run-rate in under two years on a 93% gross margin, with a funded balance sheet ($984M cash & investments vs ~$190M annual burn). If it were 30% cheaper, or if the panel had conviction voices behind it, the growth math (Street EPS of $27.52 by FY28, $64.89 by FY30) could support a tactical buy. But the setup today stacks the wrong way: a one-molecule company at ~11× sales, a first sequential revenue decline in the price action, the GLP-1 class arriving in-indication, an overbought chart (RSI 73) that has lagged the S&P for six months, only +15% to our base case against −51% to bear, and zero expert-panel coverage to lean on. We want the business; we don't want this price-and-setup combination.
- Triggers to act (either): (1) price ~$470 or below (the 200-DMA zone, ~25% margin of safety to our $610 base) with the launch intact; or (2) a clean Q2 print on 2026-08-04 — revenue at/above the ~$349.8M estimate, i.e. clear sequential reacceleration — which would justify paying up on reduced launch risk.
- Sizing if triggered: satellite only, ~0.5–1.5% of the flagship — sized for a single-asset biotech where a −50% gap on one bad readout is a live scenario, and sized below a panel-backed name of equal upside because conviction here is fundamentals-only.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-08-04). This verdict is logged as a tracked Synthos call as of 2026-07-06 at $529.48.
- Single biggest risk: the GLP-1 wave flattening the Rezdiffra curve — a launch-priced stock with a flat launch is just an expensive loss-maker.
Provenance & disclosures
- Traceability: 0 KB claims, 0 voices — the Synthos knowledge base contains no MDGL coverage, so no expert thesis is cited and
kb_net_convictionis null. Fabricated conviction is structurally impossible (claim-ID reconciliation); on this name there is simply nothing to reconcile. This is a fundamentals-driven note on a momentum-screen-surfaced name. - Data as-of: fundamentals 2026-03-31 (Q1 2026, filed 2026-05-06) · estimates & prices 2026-07-06 (FMP pull) · expert claims: none. Forward figures are analyst consensus (FMP), labeled as estimates; 2029–2030 rows rest on only 4–5 analysts.
- Valuation assumptions (labeled): base case = FY28E consensus EPS $27.52 × 25× forward multiple, discounted ~18 months at 9% ≈ $610; bull = FY29E EPS $45.14 × 25×, discounted ~2.5 years; bear = ~4× EV/S on revenue stalled near the FY26E run-rate. Street consensus ($668.83) shown as context; we anchored to the same earnings power at a plainer multiple.
- Data-quality caveats: printed beta (−1.056) is an artifact and unusable for risk math; Q1'26 weighted shares (29.0M) conflict with the market-cap-implied count (~23.1M); the FMP profile description is stale (calls the company clinical-stage); out-year SG&A estimate rows are internally inconsistent and were disregarded; geographic segment data is empty.
- Peer caveat: the FMP-supplied peer list omits the relevant MASH/GLP-1 competitive set; judge against that cohort, not the heterogeneous list shown.
- Industry context flag: statements about GLP-1 competition entering MASH are qualitative industry context, not sourced from the data file; no figures were attached to them.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").